周四,生物科技公司Moderna股价在盘中暴跌近20%,收于64.62美元,刷新四年新低。公司此前发布的2025年业绩预期和研发投入计划引发了市场对其增长前景的担忧。
数据显示,Moderna预计2025年销售额将在25亿美元至35亿美元之间,远低于之前30亿至35亿美元的预期,也较分析师预期的37.4亿美元大幅下降。由于新冠疫苗业绩快速下滑,Moderna一直寄希望于新型疫苗推出后拉动收入,但当前的营收预期令市场失望。
此外,公司还计划在2027年将年度研发费用削减至36亿-38亿美元,总计减少约11亿美元。虽然有利于降低成本,但部分分析人士担心这可能会限制公司未来的创新动力。根据相关信息,Moderna暂停了部分药品开发或取消了一些项目,以调整研究支出步伐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.